<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01123473</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-40071</org_study_id>
    <secondary_id>EU-21036</secondary_id>
    <secondary_id>2009-011580-36</secondary_id>
    <nct_id>NCT01123473</nct_id>
  </id_info>
  <brief_title>Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer</brief_title>
  <official_title>Effectiveness of First Line Treatment With Lapatinib and ECF/X in Histologically Proven Adenocarcinoma of the Stomach or the Esophagogastric Junction, Metastatic or Not Amenable to Curative Surgery According to HER2 and EGFR Status: a Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as epirubicin hydrochloride, cisplatin,&#xD;
      fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. Lapatinib ditosylate may stop&#xD;
      the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not&#xD;
      yet known whether giving combination chemotherapy together with or without lapatinib&#xD;
      ditosylate is more effective in treating patients with cancer of the stomach or&#xD;
      gastroesophageal junction.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well epirubicin hydrochloride,&#xD;
      cisplatin, and fluorouracil or capecitabine works when given together with or without&#xD;
      lapatinib ditosylate as first-line therapy in treating patients with stomach cancer or&#xD;
      gastroesophageal junction cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the activity of first-line treatment comprising epirubicin hydrochloride,&#xD;
           cisplatin, and fluorouracil or capecitabine with or without lapatinib ditosylate in&#xD;
           patients with adenocarcinoma of the stomach or esophagogastric junction that is&#xD;
           metastatic or not amenable to curative surgery according to HER2 and EGFR status.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To explore the activity of this regimen in patients who are HER2 negative by FISH, but&#xD;
           HER2 positive by IHC (2+ and 3+) as well as patients who are HER2 positive or negative&#xD;
           by FISH and negative by IHC (0 or 1+), but EGFR positive by FISH or by IHC (2+ and 3+).&#xD;
&#xD;
        -  To assess the concordance of HER2 determination by FISH and IHC.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to institution and&#xD;
      the combination of EGFR/HER2 status as determined by fluorescence in situ hybridization&#xD;
      (FISH) and immunohistochemistry (IHC) assays (HER2 positive by FISH/HER2 positive by IHC 2/3+&#xD;
      vs HER2 negative by FISH/HER2 positive by IHC 2/3+ vs HER2 negative by IHC 0/1+/EGFR positive&#xD;
      by FISH or by IHC 2/3+). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (experimental): Patients receive epirubicin hydrochloride IV and cisplatin IV on&#xD;
           day 1; fluorouracil IV continuously on days 1-21 or oral capecitabine twice daily on&#xD;
           days 1-21; and oral lapatinib ditosylate once daily on days 1-21. Treatment repeats&#xD;
           every 21 days for 6 courses in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
        -  Arm II (control): Patients receive epirubicin hydrochloride, cisplatin, and fluorouracil&#xD;
           or capecitabine as in arm I. Patients also receive oral placebo once daily on days 1-21.&#xD;
           Treatment repeats every 21 days for 6 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 8 weeks, every 3 months for 2&#xD;
      years, and then every 6 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    company withdrew interest&#xD;
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance of diagnostic tests</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Adenocarcinoma of the Gastroesophageal Junction</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Lapatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy + lapatinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Chemotherapy + placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>Lapatinib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Lapatinib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
    <arm_group_label>Lapatinib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>Lapatinib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib ditosylate</intervention_name>
    <arm_group_label>Lapatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the stomach or the esophagogastric junction&#xD;
&#xD;
               -  Metastatic disease OR not amenable to curative surgery&#xD;
&#xD;
          -  Tissue material for HER2 and EGFR assessment must be available&#xD;
&#xD;
          -  Positive HER2 status by immunohistochemistry (IHC) OR positive EGFR by either&#xD;
             fluorescence in situ hybridization (FISH) or IHC at time of randomization&#xD;
&#xD;
          -  No clinical signs of CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  WBC &gt; 3 x 10^9/L&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelet count &gt; 100 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT ≤ 3 times ULN (≤ 5 times ULN in case of liver metastases)&#xD;
&#xD;
          -  Serum creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  LVEF normal by MUGA scan or ECHO&#xD;
&#xD;
          -  No serious cardiac illness within the past 6 months&#xD;
&#xD;
          -  No previous or concurrent malignancies except for adequately treated cone-biopsied&#xD;
             carcinoma in situ of the cervix or basal cell carcinoma of the skin&#xD;
&#xD;
          -  Able to swallow and retain oral medication&#xD;
&#xD;
          -  No history or evidence of interstitial pneumonitis or pulmonary fibrosis&#xD;
&#xD;
          -  No uncontrolled infections or serious illnesses, malabsorption syndrome, or medical&#xD;
             conditions including chronic alcohol abuse, hepatitis, HIV, and/or cirrhosis&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering compliance with the study protocol or follow-up schedule&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 12 months since prior neoadjuvant or adjuvant chemotherapy&#xD;
&#xD;
          -  No other investigational drugs from 28 days prior to the first dose of study treatment&#xD;
             until 30 days after the last dose of study treatment&#xD;
&#xD;
          -  At least 30 days since prior and no concurrent drugs or herbal constituents known to&#xD;
             be inducers or inhibitors of CYP3A4&#xD;
&#xD;
          -  No prior palliative systemic chemotherapy&#xD;
&#xD;
          -  No prior EGFR pathway-targeting therapy (e.g., antibodies or tyrosine kinase&#xD;
             inhibitors)&#xD;
&#xD;
          -  No concurrent traditional Chinese medicines&#xD;
&#xD;
          -  No concurrent non-drug therapies such as radiotherapy (other than for pain relief) or&#xD;
             surgery&#xD;
&#xD;
          -  No other concurrent anticancer therapy or investigational agents&#xD;
&#xD;
          -  No concurrent grapefruit or its juice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Roth</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Cantonal Universitaire de Geneve</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg Universitaetskliniken</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.P.O. Francisco Gentil - Centro De Lisboa</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Portugal</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <results_reference>
    <citation>Roth A, Moehler MH, Mauer M, et al.: Lapatinib in combination with ECF/x in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): A phase II randomized placebo controlled trial (EORTC 40071). [Abstract] J Clin Oncol 28 (Suppl 15): A-TPS205, 2010.</citation>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>May 13, 2010</study_first_submitted>
  <study_first_submitted_qc>May 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the gastroesophageal junction</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>stage IIIA gastric cancer</keyword>
  <keyword>stage IIIB gastric cancer</keyword>
  <keyword>stage IIIC gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

